US equities |
TSLA $393.86 ▲+5.81% MU $910.81 ▲+3.79% NVDA $216.46 ▲+2.60% SPCX $148.12 ▲+0.43% META $634.43 ▼-1.27% AAPL $344.38 ▼-0.96% SNDK $1,264.46 ▲+2.13% INTC $91.44 ▲+5.15%
FinancialContent

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.375 +0.395 (+19.95%)
Delayed Quote Updated: 3:39 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Acumen Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 ↗
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 26, 2024 ↗
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
News headline image
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot ↗
Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding. 
Via InvestorPlace
News headline image
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom ↗
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population. 
Via InvestorPlace
News headline image
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
News headline image
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning ↗
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
News headline image
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2023 ↗
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
News headline image
3 Promising Biotech Stocks Flying Under the Radar ↗
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
News headline image
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193 
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >